Diabetic Retinopathy Market Research Report - Global Forecast till 2025,The global diabetic retinopathy market is growing continuously and is expected to grow at a CAGR of 5.2% from 2017 to 2023.

Market Highlights

Diabetic retinopathy is an eye disease among the diabetic patients. It is of two types, namely, non-proliferative diabetic retinopathy and proliferative advanced diabetic retinopathy. Non-proliferative diabetic retinopathy is the early stage of the disease in which the blood vessels in the retina are weakened. Proliferative diabetic retinopathy is the advanced type of the disease in which the retina is deprived of oxygen due to circulation problems. Diabetic retinopathy can be diagnosed using tests such as fluorescein angiography and optical coherence tomography. The treatment involves the use of intraocular steroid injection, laser treatment, anti-VEGF therapy, vitrectomy, and others.

The market for diabetic retinopathy exhibits a potential growth with an increasing prevalence of diabetes and increasing awareness about diabetes management. Additionally, the huge demand for diagnostic tests for diabetic retinopathy also accelerates the growth of the market. The global diabetic retinopathy market is expected to grow at a CAGR of 5.2% during the forecast period.

Some of the key players in the global market are Novartis AG (Germany), Bayer (Germany), Regeneron Pharmaceuticals Inc. (U.S.), ThromboGenics (U.S.), Actavis Plc (U.K.), Sirnaomics(U.S.), Genentech (U.S.), Alimera Sciences (U.S.), Glycadia Pharmaceuticals (U.S.), Ampio Pharmaceuticals (U.S.), Kowa Group (Japan), BCN Peptides (Spain), and others.

Global Diabetic Retinopathy Market Research Report: Information by Type (Non-proliferative and Proliferative), Treatment (Anti-VEGF Drugs, Laser Photocoagulation, Vitreoretinal Surgery, Steroid Injection), by End User (Hospitals, Ambulatory Surgical Centers, Others) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Forecast till 2025 : https://www.marketresearchfuture.com/reports/diabetic-retinopathy-market-5792